What the studies show
Because teduglutide is trophic to intestinal mucosa, the Gattex label requires colonoscopy before starting and at intervals thereafter, and lists colorectal polyps and the theoretical risk of neoplasia. An intended mechanism that is also the main long-term caution.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Gattex (teduglutide) prescribing information.DailyMed, read 29 Oct 2026Route, half-life, licensed regimen, colonoscopy requirement, and the 33-amino-acid structure.
In context
Teduglutide is a 33-amino-acid analogue of glucagon-like peptide-2, approved since 2012 as Gattex in the US and Revestive in the EU for short bowel syndrome in people dependent on parenteral support. In the pivotal STEPS trial, 63% of treated patients reduced their intravenous feeding volume against 30% on placebo over 24 weeks. It is given by daily subcutaneous injection and is prescription-only everywhere LYO covers.
Teduglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Teduglutide proven to cause colorectal neoplasia risk?
What studies are behind the grade?
Is Teduglutide approved for this?
Other outcomes for Teduglutide
- AReduced parenteral support in short bowel syndrome1 phase 3 RCT (STEPS, n=86, 24 wk)
- ADays free of intravenous feeding1 phase 3 RCT (STEPS, n=86, 24 wk)
- AGastrointestinal and stoma adverse effectsadverseApproval programme
Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →